{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:03:11Z","timestamp":1793674991606,"version":"4.5.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Changes in the clinical symptoms of acute graft-versus-host disease (GVHD) are currently used to assess treatment responses. The Mount Sinai Acute GVHD International Consortium (MAGIC) consortium has recently revealed that the integration of serum biomarkers with clinical symptoms at the onset of treatment in a MAGIC composite score (MCS) more accurately predicts treatment response and 6-month nonrelapse mortality (NRM) than clinical symptoms alone. In this study, we evaluated whether the integration of serum biomarkers and clinical symptoms on day 28 (D28) would also better predict NRM than clinical response only (CRO). We analyzed data from 1135 patients receiving systemic treatment for acute GVHD and created a fourth MCS category for patients with complete resolution of symptoms and low-risk clinical biomarkers on D28. Using a classification and regression tree model with 6-month NRM as the end point, we identified status of MCS 0 or MCS 1 at D28 as responses, which we termed the MAGIC composite response (MCR). In the validation cohort (n = 309), MCR more accurately predicted 6-month NRM than CRO (area under the curve: 0.77 vs 0.69; P = .014) and demonstrated higher negative and positive predictive values. MCR correctly reclassified both clinical nonresponders and responders: 28 of 213 clinical responders (13%) became nonresponders with fivefold higher NRM (34.3% vs 6.8%, P &amp;lt; .001) and a larger group (29\/96, 30%) of clinical nonresponders became responders with sixfold lower NRM (7.6% vs 50.7%, P &amp;lt; .001). These findings support the use of MCR as a superior surrogate end point for long-term GVHD control and survival in future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017116","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T19:49:05Z","timestamp":1755287345000},"page":"5763-5773","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"},{"name":"2Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6236-4471","authenticated-orcid":false,"given":"Joseph","family":"Portelli","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7955-1119","authenticated-orcid":false,"given":"Nikolaos","family":"Katsivelos","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2716-5792","authenticated-orcid":false,"given":"Ioannis E.","family":"Louloudis","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0196-806X","authenticated-orcid":false,"given":"Paibel","family":"Aguayo-Hiraldo","sequence":"additional","affiliation":[{"name":"3Division of Bone Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"4Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantiya","family":"Chanswangphuwana","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Choe","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Blood and Marrow Transplantation Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Etra","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"8Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[{"name":"9Pediatric Hematology\/Oncology Division, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-4046","authenticated-orcid":false,"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[{"name":"11Department of Pediatric Hematology\/Oncology and of Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-1960","authenticated-orcid":false,"given":"Timothy S.","family":"Olson","sequence":"additional","affiliation":[{"name":"12Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[{"name":"13Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":false,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology and Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Schechter","sequence":"additional","affiliation":[{"name":"16Division of Hematology\/Oncology\/Blood and Marrow Transplant, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Marx","sequence":"additional","affiliation":[{"name":"17Department of Medicine A, Hematology and Oncology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-1192","authenticated-orcid":false,"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, Experimental Immunology and Cell Therapy, Goethe University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Vasova","sequence":"additional","affiliation":[{"name":"19Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[{"name":"20Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"W\u00f6lfl","sequence":"additional","affiliation":[{"name":"21Department of Pediatrics, Children's Hospital, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"22Department of Medicine I, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Baez","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Eng","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Gleich","sequence":"additional","affiliation":[{"name":"20Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kowalyk","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Morales","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spyrou","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Young","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"23Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"24Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"25Department of Hematology\/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-7828","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L. M.","family":"Ferrara","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"9674","key":"2025112508561942000_bib1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"2025112508561942000_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjh.16190","article-title":"Advances in understanding the pathogenesis of graft-versus-host disease","volume":"187","author":"Zeiser","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"2025112508561942000_bib3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","article-title":"Graft-versus-host disease treatment: predictors of survival","volume":"16","author":"Levine","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2025112508561942000_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbmt.2009.03.012","article-title":"Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement","volume":"15","author":"Martin","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"26","key":"2025112508561942000_bib5","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2009-12-258442","article-title":"The best endpoint for acute GVHD treatment trials","volume":"115","author":"MacMillan","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2025112508561942000_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2011.41","article-title":"Prognostic value of response after upfront therapy for acute GVHD","volume":"47","author":"Saliba","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2025112508561942000_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3324\/haematol.2013.093062","article-title":"Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease","volume":"99","author":"Inamoto","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2025112508561942000_bib8","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2011-10-387357","article-title":"Plasma biomarkers of lower gastrointestinal and liver acute GVHD","volume":"119","author":"Harris","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2025112508561942000_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2025112508561942000_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood-2008-07-167098","article-title":"A biomarker panel for acute graft-versus-host disease","volume":"113","author":"Paczesny","year":"2009","journal-title":"Blood"},{"issue":"16","key":"2025112508561942000_bib11","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1182\/bloodadvances.2023009885","article-title":"Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2025112508561942000_bib12","doi-asserted-by":"crossref","first-page":"e124015","DOI":"10.1172\/jci.insight.124015","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"3","author":"Hartwell","year":"2018","journal-title":"JCI Insight"},{"issue":"17","key":"2025112508561942000_bib13","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2023009929","article-title":"The utility of biomarkers in acute GVHD prognostication","volume":"7","author":"Spyrou","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2025112508561942000_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood.2024025106","article-title":"Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD","volume":"144","author":"Akahoshi","year":"2024","journal-title":"Blood"},{"issue":"25","key":"2025112508561942000_bib15","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2025112508561942000_bib16","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/bloodadvances.2022007296","article-title":"Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification","volume":"6","author":"Etra","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2025112508561942000_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2025112508561942000_bib18","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1182\/blood-2011-08-375006","article-title":"Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease","volume":"118","author":"Ferrara","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2025112508561942000_bib19","first-page":"10.e1","article-title":"Serial clinical and biomarker monitoring during graft-versus-host disease treatment identifies distinct risk strata including an ultra-low risk group","volume":"31","author":"Katsivelos","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2025112508561942000_bib20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/bloodadvances.2023012091","article-title":"Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis","volume":"8","author":"Akahoshi","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"2025112508561942000_bib21","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2025112508561942000_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2025112508561942000_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2025112508561942000_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2009.02.007","article-title":"Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences","volume":"15","author":"Sorror","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"308","key":"2025112508561942000_bib25","doi-asserted-by":"crossref","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","article-title":"ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"11","key":"2025112508561942000_bib26","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1172\/JCI99261","article-title":"Survival signal REG3\u03b1 prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest"},{"issue":"11","key":"2025112508561942000_bib27","first-page":"1061","article-title":"Differences in acute graft-versus-host disease (GVHD) severity and its outcomes between black and white patients","volume":"30","author":"Rios","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"23","key":"2025112508561942000_bib28","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","article-title":"The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease","volume":"3","author":"Srinagesh","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2025112508561942000_bib29","first-page":"603.e1","article-title":"A validated risk stratification that incorporates MAGIC biomarkers predicts long-term outcomes in pediatric patients with acute GVHD","volume":"30","author":"Qayed","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2025112508561942000_bib30","author":"Efron","year":"1994","edition":"1st ed"},{"issue":"7","key":"2025112508561942000_bib31","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3348\/kjr.2024.0049","article-title":"Statistical methods for comparing predictive values in medical diagnosis","volume":"25","author":"Park","year":"2024","journal-title":"Korean J Radiol"},{"issue":"30","key":"2025112508561942000_bib32","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"issue":"25","key":"2025112508561942000_bib33","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"2025112508561942000_bib34","author":"Breiman","year":"1984","edition":"1st ed"},{"issue":"3","key":"2025112508561942000_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"17","key":"2025112508561942000_bib36","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1182\/bloodadvances.2023009853","article-title":"Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease","volume":"7","author":"Al Malki","year":"2023","journal-title":"Blood Adv"},{"key":"2025112508561942000_bib37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016233","article-title":"Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC","author":"Akahoshi","year":"1  2025","journal-title":"Blood Adv"},{"issue":"5","key":"2025112508561942000_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.2022017442","article-title":"Effective treatment of low-risk acute GVHD with itacitinib monotherapy","volume":"141","author":"Etra","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025112508561942000_bib39","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/bloodadvances.2021005885","article-title":"Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease","volume":"6","author":"Akahoshi","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2025112508561942000_bib40","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1093\/cid\/ciaa1871","article-title":"Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality","volume":"73","author":"Akahoshi","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2025112508561942000_bib41","first-page":"421","article-title":"A day 14 endpoint for acute GVHD clinical trials","volume":"30","author":"Spyrou","year":"2024","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5763\/2420153\/blooda_adv-2025-017116-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5763\/2420153\/blooda_adv-2025-017116-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:56:26Z","timestamp":1764078986000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5763\/546739\/The-MAGIC-composite-response-a-novel-end-point"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":41,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017116","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,13]]}}}